Where Will Kestra Medical Stock Be in 1 Year?
Kestra Medical Technologies (NASDAQ:KMTS) is a medical device startup that…
Sell
36
CCI Quote, Financials, Valuation and Earnings
Last price:
$103.19
Seasonality move
:
2.07%
Day range:
$100.32 - $103.02
52-week range:
$84.20 - $120.92
Dividend yield:
5.62%
P/E ratio:
33.72x
P/S ratio:
7.45x
P/B ratio:
7.80x
Volume:
5.3M
Avg. volume:
3M
1-year change:
6.25%
Market cap:
$44.6B
Revenue:
$6.6B
EPS (TTM):
-$10.76
Analysts' Opinion
-
Consensus RatingCrown Castle has received a consensus rating of Hold. The company's average rating is a Hold based on 6 Buy ratings, 12 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $114.01, Crown Castle has an estimated upside of 11.2% from its current price of $102.53.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $97.00 representing 100% downside risk from its current price of $102.53.
Fair Value
-
According to the consensus of 18 analysts, Crown Castle has 11.2% upside to fair value with a price target of $114.01 per share.
CCI vs. S&P 500
-
Over the past 5 trading days, Crown Castle has overperformed the S&P 500 by 3.44% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Crown Castle does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Crown Castle revenues have been falling on a year-over-year basis for 7 quarters in a row. In the most recent quarter Crown Castle reported revenues of $1.1B.
Earnings Growth
-
Crown Castle has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Crown Castle reported earnings per share of -$1.07.
Enterprise value:
69B
EV / Invested capital:
2.98x
Price / LTM sales:
7.45x
EV / EBIT:
30.52x
EV / Revenue:
11.52x
PEG ratio (5yr expected):
--
EV / Free cash flow:
38.96x
Price / Operating cash flow:
25.21x
Enterprise value / EBITDA:
16.82x
Gross Profit (TTM):
$4.3B
Return On Assets:
-13.07%
Net Income Margin (TTM):
-78.12%
Return On Equity:
-149.84%
Return On Invested Capital:
-17.29%
Operating Margin:
49.29%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $7B | $6.3B | $6B | $1.1B | $1.1B | |
| Gross Profit | $4.9B | $4.6B | $4.3B | $842M | $793M | |
| Operating Income | $2.4B | $2.4B | $2.2B | $537M | $523M | |
| EBITDA | $4.1B | $3.8B | -$1.3B | $709M | $694M | |
| Diluted EPS | $3.86 | $3.20 | -$10.76 | $0.71 | -$1.07 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.2B | $1.3B | $1.3B | $977M | $1.1B | |
| Total Assets | $38.8B | $39.1B | $39.1B | $38.2B | $31.8B | |
| Current Liabilities | $1.9B | $1.8B | $2.5B | $2.3B | $3B | |
| Total Liabilities | $29.8B | $31B | $31.8B | $32.2B | $33B | |
| Total Equity | $8.9B | $8B | $7.2B | $6B | -$1.3B | |
| Total Debt | $19.9B | $21.1B | $22.3B | $23.4B | $24.4B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $2.9B | $3.1B | $3B | $599M | $641M | |
| Cash From Investing | -$1.5B | -$1.4B | -$1.2B | -$320M | -$255M | |
| Cash From Financing | -$1.6B | -$1.8B | -$1.9B | -$261M | -$403M | |
| Free Cash Flow | $1.6B | $2B | $1.8B | $552M | $601M | |
CCI
Sector
Market Cap
$44.6B
$1B
Price % of 52-Week High
84.79%
83.33%
Dividend Yield
5.62%
3.1%
Shareholder Yield
5.42%
4.07%
1-Year Price Total Return
6.25%
--
Beta (5-Year)
0.878
0.756
Dividend yield:
5.62%
Annualized payout:
$6.26
Payout ratio:
-58.38%
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$99.72
200-day SMA
Buy
Level
$101.61
Bollinger Bands (100)
Buy
Level
93.18 - 103.88
Chaikin Money Flow
Buy
Level
542.8M
20-day SMA
Buy
Level
$99.85
Relative Strength Index (RSI14)
Buy
Level
59.28
ADX Line
Buy
Level
15.94
Williams %R
Sell
Level
-9.5517
50-day SMA
Buy
Level
$101.22
MACD (12, 26)
Sell
Level
-0.27
25-day Aroon Oscillator
Sell
Level
-52
On Balance Volume
Neutral
Level
266.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.2117)
Sell
CA Score
(Annual)
Level (-2.6634)
Buy
Beneish M-Score
(Annual)
Level (-3.524)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (2.1389)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (3)
Sell
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Crown Castle owns and leases roughly 40,000 cell towers in the United States. It also owns more than 90,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. Crown Castle’s towers and fiber are predominantly in the largest US cities. The company has a very concentrated customer base, with about 75% of its revenue from the Big Three US mobile carriers. Crown Castle operates as a real estate investment trust. It has announced plans to divest its fiber business, which should be finalized in 2026. After that, Crown will be a stand-alone tower operator.
Stock Forecast FAQ
In the current month, CCI has received 6 Buy ratings 12 Hold ratings, and 0 Sell ratings. The CCI average analyst price target in the past 3 months is $114.01.
-
Where Will Crown Castle Stock Be In 1 Year?
According to analysts, the consensus estimate is that Crown Castle share price will rise to $114.01 per share over the next 12 months.
-
What Do Analysts Say About Crown Castle?
Analysts are divided on their view about Crown Castle share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Crown Castle is a Sell and believe this share price will drop from its current level to $97.00.
-
What Is Crown Castle's Price Target?
The price target for Crown Castle over the next 1-year time period is forecast to be $114.01 according to 18 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 12 analysts rate the stock a Hold.
-
Is CCI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Crown Castle is a Hold. 12 of 18 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of CCI?
You can purchase shares of Crown Castle via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Crown Castle shares.
-
What Is The Crown Castle Share Price Today?
Crown Castle was last trading at $103.19 per share. This represents the most recent stock quote for Crown Castle. Yesterday, Crown Castle closed at $102.53 per share.
-
How To Buy Crown Castle Stock Online?
In order to purchase Crown Castle stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Howard Marks Buy Grab Stock?
When a legendary value investor who cut his teeth in…
Why Did Warren Buffett Buy Amazon Stock?
When investors think of tech stocks in Warren Buffett’s portfolio,…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 41x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
88
CDTX alert for Jun 24
Cidara Therapeutics [CDTX] is up 3.18% over the past day.
Sell
46
HIMS alert for Jun 24
Hims & Hers Health [HIMS] is up 2.26% over the past day.
Buy
67
WGS alert for Jun 24
GeneDx Holdings [WGS] is up 13.99% over the past day.
